Parexel will go private in $5B deal

Massachusetts-based Parexel International Corp. has agreed to be acquired by a private equity firm for $5 billion. Parexel (Nasdaq: PRXL) said it would be acquired by Pamplona Capital Management LLP. As a result of the deal, which is expected to close in the fourth quarter of 2017, Parexel will become a privately held company. As a contract research organization, Parexel does not develop its own drugs, but is paid by drug developers to run clinical trials and provide other services. The Wall Street…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news